E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
macular edema following cataract surgery |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10051240 |
E.1.2 | Term | Cystoid macular edema |
|
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 9.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10054467 |
E.1.2 | Term | Macular edema |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Demonstrate superiority of NEVANAC® (nepafenac ophthalmic suspension) 0.1% relative to nepafenac vehicle based on the percentage of diabetic retinopathy patients who develop macular edema (defined as ≥30% increase from pre-operative baseline in central subfield macular thickness) within 90 days following cataract surgery. |
|
E.2.2 | Secondary objectives of the trial |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
1) Patients must be 18 years of age and older, of any race and either sex, who have a cataract, and are planning to undergo cataract extraction by phacoemulsification with the implantation of a posterior chamber intraocular lens into the lens capsule 2) History of Type 1 or Type 2 diabetes 3) NPDR (mild, moderate or severe) in the study eye as defined by the International Clinical Diabetic Retinopathy Disease Severity Scale
4) Central subfield macular thickness ≤ 320 µm in the study eye prior to cataract surgery as determined by SD-OCT and confirmed by the reading center 5) Absence of CME or cystoid abnormalities in the study eye as detected by SD-OCT and confirmed by the reading center 6) Absence of clinically significant macular edema (CSME) in the study eye as detected by clinical exam
|
|
E.4 | Principal exclusion criteria |
Exclusions related to patient history or current ocular conditions: 4) Signs of vitreomacular traction or epiretinal membrane in the study eye as detected by SD-OCT or fundus exam per reading center or investigator 5) Current or previous ocular disease in the study eye that in the opinion of the investigator may confound assessment of the macula, the retina, or central vision, other that diabetic retinopathy, such as retinal vascular disease, macular surgery, retinal detachment involving the macula, wet macular degeneration or geographic atrophy in the study eye 6) Prior focal photocoagulation for the treatment of diabetic macular edema in the study eye within 6 months of the pre-operative baseline visit (Note: peripheral retina treatment for retinal tear or lattice degeneration is permitted) 7) Prior panretinal photocoagulation in the study eye 8) Planned multiple procedures for study eye during the cataract/IOL implantation surgery (e.g., trabeculoplasty, corneal transplant) 9) Patients who have received corneal transplants in the study eye 10) Use of daily doses of topical ocular NSAIDs (Voltaren, Acular LS, etc.), in the study eye, within 7 days prior to surgery 11) Use of daily doses of systemic NSAIDs (ibuprofen, naproxen, etc.) within 7 days prior to surgery (through study exit), with the exception of 325 mg of aspirin which will be allowed during the study. 12) Use of systemic steroids within 14 days prior to surgery (through study exit) 13) Use of daily doses of topical ocular NSAIDs (Voltaren, Acular LS, etc.) in the nonstudy eye through study exit (Note: All topical ocular NSAIDs must be discontinued 1 day prior to surgery) 14) Use of daily doses of topical ocular steroids in the nonstudy eye through study exit (Note: All topical ocular steroids must be discontinued 1 day prior to surgery) 15) Use of topical ocular steroids, in the study eye, within 14 days prior to surgery 16) Treatment with intraocular or periocular steroids in the study eye within 6 months prior to surgery
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
percentage of patients who develop macular edema (defined as ≥30% increase from pre-operative baseline in central subfield macular thickness) within 90 days following cataract surgery |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | Yes |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 22 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | Yes |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.6.3 | If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Enrollment of approximately 260 patients (130 per treatment group) to obtain 222 patients who are evaluable per protocol (111 per treatment group) |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 0 |
E.8.9.1 | In the Member State concerned days | 0 |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 0 |
E.8.9.2 | In all countries concerned by the trial days | 0 |